Serum IGFBP-1 as a promising diagnostic and prognostic biomarker for colorectal cancer

Sci Rep. 2024 Jan 22;14(1):1839. doi: 10.1038/s41598-024-52220-2.

Abstract

Our previous study showed that levels of circulating insulin-like growth factor binding protein-1 (IGFBP-1) has potential diagnostic value for early-stage upper gastrointestinal cancers. This study aimed to assess whether serum IGFBP-1 is a potential diagnostic and prognostic biomarker for CRC patients. IGFBP-1 mRNA expression profile data of peripheral blood in colorectal cancer (CRC) patients were downloaded and analyzed from Gene Expression Omnibus database. We detected serum IGFBP-1 in 138 CRC patients and 190 normal controls using enzyme-linked immunosorbent assay. Blood IGFBP-1 mRNA levels were higher in CRC patients than those in normal controls (P = 0.027). In addition, serum IGFBP-1 protein levels in the CRC group were significantly higher than those in normal control group (P < 0.0001). Serum IGFBP-1 demonstrated better diagnostic accuracy for all CRC and early-stage CRC, respectively, when compared with carcinoembryonic antigen (CEA), carbohydrate antigen19-9 (CA 19-9) or the combination of CEA and CA19-9. Furthermore, Cox multivariate analysis revealed that serum IGFBP-1 was an independent prognostic factor for OS (HR = 2.043, P = 0.045). Our study demonstrated that serum IGFBP-1 might be a potential biomarker for the diagnosis and prognosis of CRC. In addition, the nomogram might be helpful to predict the prognosis of CRC.

MeSH terms

  • Carcinoembryonic Antigen
  • Colorectal Neoplasms* / diagnosis
  • Colorectal Neoplasms* / genetics
  • Humans
  • Insulin-Like Growth Factor Binding Protein 1*
  • Prognosis
  • RNA, Messenger

Substances

  • Insulin-Like Growth Factor Binding Protein 1
  • Carcinoembryonic Antigen
  • RNA, Messenger